Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

被引：136

作者：

Jain, Tania ^{[1
,2
]}

Bar, Merav ^{[3
,4
]}

Kansagra, Ankit J. ^{[5
]}

Chong, Elise A. ^{[6
]}

Hashmi, Shahrukh K. ^{[7
,8
]}

Neelapu, Sattva S. ^{[9
]}

Byrne, Michael ^{[10
]}

Jacoby, Elad ^{[11
]}

Lazaryan, Aleksandr ^{[12
]}

Jacobson, Caron A. ^{[13
]}

Ansell, Stephen M. ^{[7
]}

Awan, Farrukh T. ^{[5
]}

Burns, Linda ^{[14
,15
]}

Bachanova, Veronika ^{[16
]}

Bollard, Catherine M. ^{[17
]}

Carpenter, Paul A. ^{[3
,4
,18
]}

DiPersio, John F. ^{[19
]}

Hamadani, Mehdi ^{[20
]}

Heslop, Helen E. ^{[21
]}

Hill, Joshua A. ^{[3
,4
,22
]}

Komanduri, Krishna, V ^{[23
]}

Kovitz, Craig A. ^{[24
]}

Lazarus, Hillard M. ^{[25
]}

Serrette, Justin M. ^{[26
]}

Mohty, Mohamad ^{[27
]}

Miklos, David ^{[28
]}

Nagler, Arnon ^{[10
]}

Pavletic, Steven Z. ^{[29
]}

Savani, Bipin N. ^{[10
]}

Schuster, Stephen J. ^{[6
]}

Kharfan-Dabaja, Mohamed A. ^{[30
,31
]}

Perales, Miguel-Angel ^{[1
,32
]}

Lin, Yi ^{[7
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Adult Bone Marrow Transplant Serv, 1275 York Ave, New York, NY 10021 USA

[2] Johns Hopkins Univ, Sch Med, Hematol Malignancies & Bone Marrow Transplantat P, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[3] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98195 USA

[4] Univ Washington, Dept Med, Seattle, WA 98195 USA

[5] Univ Texas Southwestern Med Ctr Dallas, Dept Hematol & Oncol, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75390 USA

[6] Univ Penn, Abramson Canc Ctr, Lymphoma Program, Philadelphia, PA 19104 USA

[7] Mayo Clin, Div Hematol, Rochester, MN USA

[8] King Faisal Specialist Hosp & Res Ctr, Oncol Ctr, Riyadh, Saudi Arabia

[9] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[10] Vanderbilt Univ, Med Ctr, Div Hematol & Med Oncol, Nashville, TN USA

[11] Tel Aviv Univ, Chaim Sheba Med Ctr, Sackler Sch Med, Tel Aviv, Israel

[12] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplant & Cellular Immunotherap, Tampa, FL USA

[13] Dana Farber Canc Inst, Immune Effector Cell Therapy Program, Boston, MA 02115 USA

[14] Natl Marrow Donor Program, Minneapolis, MN USA

[15] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA

[16] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA

[17] Childrens Natl Hlth Syst, Ctr Canc & Immunol Res, Washington, DC USA

[18] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA

[19] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA

[20] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI 53226 USA

[21] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA

[22] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA

[23] Sylvester Comprehens Canc Ctr, Div Transplantat & Cellular Therapy, Miami, FL USA

[24] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gen Oncol, Houston, TX 77030 USA

[25] Case Western Reserve Univ, Div Hematol & Oncol, Cleveland, OH 44106 USA

[26] Univ Texas Med Branch, Dept Pediat, Galveston, TX 77555 USA

[27] Sorbonne Univ, St Antoine Hosp, AP HP, Hematol & Cellular Therapy Dept,INSERM UMRs 938, Paris, France

[28] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA

[29] NCI, Graft Versus Host & Late Effects Sect, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[30] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA

[31] Mayo Clin, Blood & Marrow Transplantat Program, Jacksonville, FL 32224 USA

[32] Weill Cornell Med Coll, Dept Med, New York, NY USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2019年 / 25卷 / 12期

关键词：

Chimeric antigen receptor T cell therapy; Diffuse large B cell lymphoma; Non-Hodgkin lymphoma; HUMORAL IMMUNITY; SALVAGE REGIMENS; BENDAMUSTINE; MALIGNANCIES; IBRUTINIB; TISAGENLECLEUCEL; IMMUNOTHERAPY; NEUROTOXICITY; CHEMOTHERAPY; MAINTENANCE;

D O I：

10.1016/j.bbmt.2019.08.015

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Axicabtagene ciloleucel (YESCARTA; Kite Pharma, a Gilead Company, Los Angeles CA) and tisagenlecleucel (KYM-RIAH; Novartis Pharmaceuticals Corp., Basel, Switzerland) are two CD19-directed chimeric antigen receptor (CAR) T cell products currently approved by the US Food and Drug Administration; the European Medicines Agency; Health Canada; Ministry of Health, Labor and Welfare (Japan); and Therapeutic Goods Administration (Australia) for treatment of specific subtypes of relapsed refractory aggressive B cell non-Hodgkin lymphoma (NHL). Although this approval has been transformative in the use of cellular immunotherapy in lymphoma, there are concerns regarding appropriate use of this novel therapy and of short- and long-term toxicities. To address these issues, representatives of the American Society of Transplantation and Cellular Therapy convened to recognize and address key issues surrounding the clinical application of CD19 CART cell therapy in B cell lymphomas, in collaboration with worldwide experts. The aim of this article is to provide consensus opinion from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the use of CD19 CART cell products for the treatment of NHL. As the clinical practice using CAR T cells grows worldwide, we anticipate that this guidance will be relevant for hematology/oncology physicians who care for patients with lymphomas. (C) 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

引用

页码：2305 / 2321

页数：17

共 99 条

[1] Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma [J].

Abramson, Jeremy S. ;

McGree, Brianne ;

Noyes, Sarah ;

Plummer, Sean ;

Wong, Curtis ;

Chen, Yi-Bin ;

Palmer, Edwin ;

Albertson, Tina ;

Ferry, Judith A. ;

Arrillaga-Romany, Isabel C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (08) :783-784

[2] Maintenance of the plasma cell pool is independent of memory B cells [J].

Ahuja, Anupama ;

Anderson, Shannon M. ;

Khalil, Ashraf ;

Shlomchik, Mark J. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (12) :4802-4807

[3]

[Anonymous], 2018, BLOOD S1, DOI DOI 10.1182/BLOOD-2018-99-117133

[4]

[Anonymous], 2018, BIOL BLOOD MARROW TR, V24, P880

[5]

[Anonymous], 2018, BLOOD S1, DOI [DOI 10.1182/blood-2018-99-114152, DOI 10.1182/BLOOD-2018-99-114152]

[6]

[Anonymous], ONCOIMMUNOLOGY

[7] Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy [J].

Bhoj, Vijay G. ;

Arhontoulis, Dimitrios ;

Wertheim, Gerald ;

Capobianchi, James ;

Callahan, Colleen A. ;

Ellebrecht, Christoph T. ;

Obstfeld, Amrom E. ;

Lacey, Simon F. ;

Melenhorst, Jan J. ;

Nazimuddin, Farzana ;

Hwang, Wei-Ting ;

Maude, Shannon L. ;

Wasik, Mariusz A. ;

Bagg, Adam ;

Schuster, Stephen ;

Feldman, Michael D. ;

Porter, David L. ;

Grupp, Stephen A. ;

June, Carl H. ;

Milone, Michael C. .

BLOOD, 2016, 128 (03) :360-370

[8] PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts [J].

Bishop, David C. ;

Xu, Ning ;

Tse, Benjamin ;

O'Brien, Tracey A. ;

Gottlieb, David J. ;

Dolnikov, Alla ;

Micklethwaite, Kenneth P. .

MOLECULAR THERAPY, 2018, 26 (08) :1883-1895

[9] Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion [J].

Bishop, Michael R. ;

Maziarz, Richard T. ;

Waller, Edmund K. ;

Jaeger, Ulrich ;

Westin, Jason R. ;

McGuirk, Joseph P. ;

Fleury, Isabelle ;

Holte, Harald ;

Borchmann, Peter ;

del Corral, Christopher ;

Tiwari, Ranjan ;

Anak, Oezlem ;

Awasthi, Rakesh ;

Pacaud, Lida ;

Romanov, Vadim V. ;

Schuster, Stephen J. .

BLOOD ADVANCES, 2019, 3 (14) :2230-2236

[10] Toxicity and management in CAR T-cell therapy [J].

Bonifant, Challice L. ;

Jackson, Hollie J. ;

Brentjens, Renier J. ;

Curran, Kevin J. .

MOLECULAR THERAPY-ONCOLYTICS, 2016, 3 :16011

← 1 2 3 4 5 6 7 8 9 10 →